Lupus Nephritis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Prevalence, Therapies, MOA, ROA, and Companies by DelveInsight

Lupus Nephritis companies are Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Otsuka Pharmaceutical, MorphoSys, Vertice Pharma, Pharmaceutical Associates Inc., Sun Pharmaceutical, Abbott, Johnson & Johnson Private Limited, Bayer, Sanofi, Sumitomo Corporation, LEO Pharma A/S, Cipla, and Nimble Pharmaceuticals, and others.
(Albany, USA) DelveInsight's "Lupus Nephritis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Lupus Nephritis, historical and forecasted epidemiology as well as the Lupus Nephritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Lupus Nephritis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Lupus Nephritis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Lupus Nephritis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Lupus Nephritis market.

Request for a Free Sample Report @ Lupus Nephritis Market Forecast [https://www.delveinsight.com/report-store/lupus-nephritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some facts of the Lupus Nephritis Market Report are:

* According to DelveInsight, Lupus Nephritis market size is expected to grow at a decent CAGR by 2034.
* The total lupus nephritis market size in the 7MM is approximately USD 1,120 million in 2022 and is projected to increase during the forecast period (2023-2034).
* In the total market size of Lupus Nephritis in the 7MM, the United States accounted for the highest market share that is more than 80% in 2023, followed by Japan and the Spain.
* Leading Lupus Nephritis companies working in the market are Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Otsuka Pharmaceutical, MorphoSys, Vertice Pharma, Pharmaceutical Associates Inc., Sun Pharmaceutical, Abbott, Johnson & Johnson Private Limited, Bayer, Sanofi, Sumitomo Corporation, LEO Pharma A/S, Cipla, and Nimble Pharmaceuticals, and others.
* Key Lupus Nephritis Therapies expected to launch in the market are BENLYSTA (belimumab), LUPKYNIS (voclosporin), Ianalumab (VAY736), SAPHNELO (anifrolumab), GAZYVA/GAZYVARO (obinutuzumab), Anifrolumab and others.
* In February 2025, the FDA cleared Allogene Therapeutics' investigational new drug (IND) application for ALLO-329, an allogenic CAR-T cell therapy. Researchers are set to begin the Phase 1 RESOLUTION trial in mid-2025 for autoimmune diseases, including systemic lupus erythematosus (SLE), lupus nephritis (LN), idiopathic inflammatory myopathies, and systemic sclerosis.
* In November 2024, Adicet Bio announced that the first LN patient had been dosed in the Phase I clinical trial evaluating ADI-001 in autoimmune diseases.
* In November 2024, Kyverna Therapeutics announced that it would present updated clinical data from LN patients treated with KYV-101 in ongoing Kyverna-sponsored KYSA-1 and KYSA-3 Phase I/II studies and named patient treatments.
* In October 2024, Kezar Life Sciences suspended subject enrolment and patient dosing in the Phase II PALIZADE trial of zetomipzomib for active lupus nephritis.
* In June 2024, Nkarta announced the initiation of Ntrust-I, a multi-center clinical trial of NKX019 in lupus nephritis, with the first patient in screening. The company also announced the clearance by the U.S. Food and Drug Administration (FDA) of its second Investigational New Drug (IND) application for NKX019 in autoimmune disease.
* In June 2024, Adicet Bio announced that the US Food and Drug Administration (FDA) had granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis.
* In April 2024, Caribou Biosciences announced that it had received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for CB-010, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (KO), for the treatment of lupus nephritis (LN) and extrarenal lupus (ERL). The Phase 1, multicenter, open label GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024.
* In March 2024, Artiva Therapeutics is looking to dose the first patient in a Phase I/II trial assessing its cell therapy AlloNK in lupus nephritis (LN).

Lupus Nephritis Overview

Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE), an autoimmune disease that affects multiple organs. It occurs when the immune system attacks the kidneys, causing inflammation and damage to the glomeruli, leading to impaired kidney function. LN is a major cause of morbidity in lupus patients and can progress to chronic kidney disease (CKD) or end-stage renal disease (ESRD) if untreated.

Symptoms of lupus nephritis vary but commonly include proteinuria, hematuria, edema (especially in the legs and face), hypertension, and declining kidney function. Diagnosis is confirmed through kidney biopsy, which helps classify LN into different histological classes based on severity. Blood tests, urine analysis, and estimated glomerular filtration rate (eGFR) are also essential for disease monitoring.

Lupus nephritis Treatment focuses on reducing inflammation, preserving kidney function, and preventing flare-ups. Immunosuppressive therapy with corticosteroids, mycophenolate mofetil (MMF), or cyclophosphamide is the standard approach. In refractory cases, biologics like belimumab or rituximab may be used. Blood pressure control with ACE inhibitors or angiotensin receptor blockers (ARBs) is crucial in managing proteinuria.

Early Lupus nephritis diagnosis and aggressive treatment are essential to improving prognosis and preventing kidney failure in lupus nephritis patients.

Learn more about Lupus Nephritis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ [https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Lupus Nephritis Market

The Lupus Nephritis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Lupus Nephritis market trends by analyzing the impact of current Lupus Nephritis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Lupus Nephritis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Lupus Nephritis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Lupus Nephritis market in 7MM is expected to witness a major change in the study period 2020-2034.

Lupus Nephritis Epidemiology

The Lupus Nephritis epidemiology section provides insights into the historical and current Lupus Nephritis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Lupus Nephritis market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Lupus Nephritis Epidemiology @ Lupus Nephritis Market Dynamics [https://www.delveinsight.com/report-store/lupus-nephritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Lupus Nephritis Drugs Uptake

This section focuses on the uptake rate of the potential Lupus Nephritis drugs recently launched in the Lupus Nephritis market or expected to be launched in 2020-2034. The analysis covers the Lupus Nephritis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Lupus Nephritis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Lupus Nephritis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Lupus Nephritis Pipeline Development Activities

The Lupus Nephritis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Lupus Nephritis key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Lupus Nephritis pipeline development activities @ [https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Lupus Nephritis Therapeutics Assessment

Major key companies are working proactively in the Lupus Nephritis Therapeutics market to develop novel therapies which will drive the Lupus Nephritis treatment markets in the upcoming years are Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Otsuka Pharmaceutical, MorphoSys, Vertice Pharma, Pharmaceutical Associates Inc., Sun Pharmaceutical, Abbott, Johnson & Johnson Private Limited, Bayer, Sanofi, Sumitomo Corporation, LEO Pharma A/S, Cipla, and Nimble Pharmaceuticals, and others.

Learn more about the emerging Lupus Nephritis therapies & key companies @ [https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Lupus Nephritis Report Key Insights

1. Lupus Nephritis Patient Population

2. Lupus Nephritis Market Size and Trends

3. Key Cross Competition in the Lupus Nephritis Market

4. Lupus Nephritis Market Dynamics (Key Drivers and Barriers)

5. Lupus Nephritis Market Opportunities

6. Lupus Nephritis Therapeutic Approaches

7. Lupus Nephritis Pipeline Analysis

8. Lupus Nephritis Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Lupus Nephritis Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Lupus Nephritis Competitive Intelligence Analysis

4. Lupus Nephritis Market Overview at a Glance

5. Lupus Nephritis Disease Background and Overview

6. Lupus Nephritis Patient Journey

7. Lupus Nephritis Epidemiology and Patient Population

8. Lupus Nephritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Lupus Nephritis Unmet Needs

10. Key Endpoints of Lupus Nephritis Treatment

11. Lupus Nephritis Marketed Products

12. Lupus Nephritis Emerging Therapies

13. Lupus Nephritis Seven Major Market Analysis

14. Attribute Analysis

15. Lupus Nephritis Market Outlook (7 major markets)

16. Lupus Nephritis Access and Reimbursement Overview

17. KOL Views on the Lupus Nephritis Market

18. Lupus Nephritis Market Drivers

19. Lupus Nephritis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lupus-nephritis-treatment-market-2034-clinical-trials-ema-pdma-fda-approvals-medication-prevalence-therapies-moa-roa-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.